125 related articles for article (PubMed ID: 33507693)
1. The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells.
Jenie RI; Utomo RY; Susidarti RA; Novitasari D; Kirihata M; Meiyanto E
Asian Pac J Cancer Prev; 2021 Jan; 22(1):151-155. PubMed ID: 33507693
[TBL] [Abstract][Full Text] [Related]
2. Preparation of pentagamaboronon-0 and its fructose and sorbitol complexes as boron carrier for boron neutron capture therapy (BNCT) application.
Susidarti RA; Utomo RY; Qodria L; Ramadani RD; Ohta Y; Hattori Y; Kirihata M; Meiyanto E
Res Pharm Sci; 2019 Aug; 14(4):286-292. PubMed ID: 31516505
[TBL] [Abstract][Full Text] [Related]
3. CCA-1.1, a Novel Curcumin Analog, Exerts Cytotoxic anti- Migratory Activity toward TNBC and HER2-Enriched Breast Cancer Cells.
Novitasari D; Jenie RI; Utomo RY; Kato JY; Meiyanto E
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1827-1836. PubMed ID: 34181339
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol loaded oxidized mesoporous carbon nanoparticles: A promising tool to treat triple negative breast cancer.
Fan C; Kong F; Shetti D; Zhang B; Yang Y; Wei K
Biochem Biophys Res Commun; 2019 Nov; 519(2):378-384. PubMed ID: 31519327
[TBL] [Abstract][Full Text] [Related]
5. The trans-[Ru(PPh
Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
[TBL] [Abstract][Full Text] [Related]
6. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
Pindiprolu SKSS; Krishnamurthy PT; Dev C; Chintamaneni PK
Chem Phys Lipids; 2021 Mar; 235():105033. PubMed ID: 33385372
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells.
Jinih M; Wang JH; Pfirrmann RW; O'Leary DP; Corrigan MA; Redmond HP
Anticancer Res; 2021 May; 41(5):2247-2256. PubMed ID: 33952451
[TBL] [Abstract][Full Text] [Related]
8. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
9. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
10. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
12. Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro.
Eskiler GG; Cecener G; Dikmen G; Egeli U; Tunca B
Curr Drug Deliv; 2019; 16(6):511-529. PubMed ID: 31113350
[TBL] [Abstract][Full Text] [Related]
13. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).
Godugu C; Doddapaneni R; Singh M
Colloids Surf B Biointerfaces; 2017 May; 153():208-219. PubMed ID: 28249200
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model.
Maia AR; de Man J; Boon U; Janssen A; Song JY; Omerzu M; Sterrenburg JG; Prinsen MB; Willemsen-Seegers N; de Roos JA; van Doornmalen AM; Uitdehaag JC; Kops GJ; Jonkers J; Buijsman RC; Zaman GJ; Medema RH
Ann Oncol; 2015 Oct; 26(10):2180-92. PubMed ID: 26153498
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
[TBL] [Abstract][Full Text] [Related]
16. Different Cytotoxic Effects of Vetiver Oil on Three Types of Cancer Cells, Mainly Targeting CNR2 on TNBC.
Hanifa M; Wulandari R; Zulfin UM; Nugroho EP; Haryanti S; Meiyanto E
Asian Pac J Cancer Prev; 2022 Jan; 23(1):241-251. PubMed ID: 35092394
[TBL] [Abstract][Full Text] [Related]
17. Suppression of TRPM7 enhances TRAIL-induced apoptosis in triple-negative breast cancer cells.
Song C; Choi S; Oh KB; Sim T
J Cell Physiol; 2020 Dec; 235(12):10037-10050. PubMed ID: 32468675
[TBL] [Abstract][Full Text] [Related]
18. Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells.
Shrestha S; Sorolla A; Fromont J; Blancafort P; Flematti GR
Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30275391
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative and Antimigration Activities of Fluoro-Neplanocin A via Inhibition of Histone H3 Methylation in Triple-Negative Breast Cancer.
Byun WS; Kim WK; Yoon JS; Jarhad DB; Jeong LS; Lee SK
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32244385
[TBL] [Abstract][Full Text] [Related]
20. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
